A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth

Marchion,Douglas  C.; Bicaku,Elona; Xiong,Yin; Bou Zgheib,Nadim; Al Sawah,Entidhar; Stickles,Xiaomang  Ba; Judson,Patricia   L.; Lopez,Alex S.; Cubitt,Christopher  L.; Gonzalez-Bosquet,Jesus; Wenham,Robert  M.; Apte,Sachin  M.; Berglund,Anders; Lancaster,Johnathan  M.

doi:10.3892/or.2013.2329

A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth

Authors:
- Douglas C. Marchion
- Elona Bicaku
- Yin Xiong
- Nadim Bou Zgheib
- Entidhar Al Sawah
- Xiaomang Ba Stickles
- Patricia L. Judson
- Alex S. Lopez
- Christopher L. Cubitt
- Jesus Gonzalez-Bosquet
- Robert M. Wenham
- Sachin M. Apte
- Anders Berglund
- Johnathan M. Lancaster
View Affiliations

Affiliations: Department of Women's Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA, Department of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA, Translational Research Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA, Cancer Informatics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
Published online on: March 5, 2013 https://doi.org/10.3892/or.2013.2329
Pages: 2011-2018

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Elevated serum levels of hepatocyte growth factor (HGF) and high tumor expression of c-Met are both indicators of poor overall survival from ovarian cancer (OVCA). In the present study, we evaluated the role of the HGF signaling pathway in OVCA cell line chemoresistance and OVCA patient overall survival as well as the influence of HGF/c-Met signaling inhibition on the sensitivity of OVCA cells to combinational carboplatin plus paclitaxel therapy. The prevalence of the HGF receptor, c-Met, was determined by immunohistochemistry in primary OVCA samples (n=79) and OVCA cell lines (n=41). The influence of the c-Met-specific inhibitor MK8033 on OVCA cell sensitivity to combinations of carboplatin plus paclitaxel was examined in a subset of OVCA cells (n=8) by CellTiter-Blue cell viability assays. Correlation tests were used to identify genes associated with response to MK8033 and carboplatin plus paclitaxel. Identified genes were evaluated for influence on overall survival from OVCA using principal component analysis (PCA) modeling in an independent clinical OVCA dataset (n=218). Immunohistochemistry analysis indicated that 83% of OVCA cells and 92% of primary OVCA expressed the HGF receptor, c-Met. MK8033 exhibited significant anti-proliferative effects against a panel of human OVCA cell lines. Combination index values determined by the Chou-Talalay isobologram equation indicated synergistic activity in combinations of MK8033 and carboplatin plus paclitaxel. Pearson's correlation identified a 47-gene signature to be associated with MK8033-carboplatin plus paclitaxel response. PCA modeling indicated an association of this 47-gene response signature with overall survival from OVCA (P=0.013). These data indicate that HGF/c-Met pathway signaling may influence OVCA chemosensitivity and overall patient survival. Furthermore, HGF/c-Met inhibition by MK8033 represents a promising new therapeutic avenue to increase OVCA sensitivity to carboplatin plus paclitaxel.

View Figures

View References

1	Baker VV: Salvage therapy for recurrent epithelial ovarian cancer. Hematol Oncol Clin North Am. 17:977–988. 2003. View Article : Google Scholar : PubMed/NCBI
2	Omura GA, Brady MF, Homesley HD, et al: Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol. 9:1138–1150. 1991.PubMed/NCBI
3	Di Renzo MF, Narsimhan RP, Olivero M, et al: Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene. 6:1997–2003. 1991.
4	Huntsman D, Resau JH, Klineberg E and Auersperg N: Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy. Am J Pathol. 155:343–348. 1999. View Article : Google Scholar : PubMed/NCBI
5	Aune G, Lian AM, Tingulstad S, et al: Increased circulating hepatocyte growth factor (HGF): a marker of epithelial ovarian cancer and an indicator of poor prognosis. Gynecol Oncol. 121:402–406. 2011. View Article : Google Scholar : PubMed/NCBI
6	Goode EL, Chenevix-Trench G, Hartmann LC, et al: Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev. 20:1638–1648. 2011. View Article : Google Scholar : PubMed/NCBI
7	Sawada K, Radjabi AR, Shinomiya N, et al: c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 67:1670–1679. 2007. View Article : Google Scholar : PubMed/NCBI
8	Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S and Matsubara O: Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient. Mod Pathol. 24:1146–1155. 2011. View Article : Google Scholar : PubMed/NCBI
9	Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S and Matsubara O: Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas. Mod Pathol. 25:122–130. 2012. View Article : Google Scholar : PubMed/NCBI
10	Basha R, Ingersoll SB, Sankpal UT, et al: Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. Gynecol Oncol. 122:163–170. 2011. View Article : Google Scholar
11	Zillhardt M, Christensen JG and Lengyel E: An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia. 12:1–10. 2010.
12	Zillhardt M, Park SM, Romero IL, et al: Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res. 17:4042–4051. 2011. View Article : Google Scholar
13	Marchion DC, Cottrill HM, Xiong Y, et al: BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res. 17:6356–6366. 2011. View Article : Google Scholar : PubMed/NCBI
14	Bicaku E, Xiong Y, Marchion DC, et al: In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. Br J Cancer. 106:1967–1975. 2012. View Article : Google Scholar
15	Jolliffe IT: Principal Component Analysis. 2nd edition. Springer-Verlag; New York: 2002
16	Nakamura T, Nawa K and Ichihara A: Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun. 122:1450–1459. 1984. View Article : Google Scholar : PubMed/NCBI
17	Nakamura T, Teramoto H and Ichihara A: Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci USA. 83:6489–6493. 1986. View Article : Google Scholar : PubMed/NCBI
18	Nakamura T, Nawa K, Ichihara A, Kaise N and Nishino T: Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS Lett. 224:311–316. 1987. View Article : Google Scholar : PubMed/NCBI
19	Jeffers M, Rao MS, Rulong S, et al: Hepatocyte growth factor/scatter factor-Met signaling induces proliferation, migration, and morphogenesis of pancreatic oval cells. Cell Growth Differ. 7:1805–1813. 1996.PubMed/NCBI
20	Montesano R, Matsumoto K, Nakamura T and Orci L: Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell. 67:901–908. 1991. View Article : Google Scholar : PubMed/NCBI
21	Weidner KM, Di Cesare S, Sachs M, Brinkmann V, Behrens J and Birchmeier W: Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature. 384:173–176. 1996. View Article : Google Scholar : PubMed/NCBI
22	Bladt F, Riethmacher D, Isenmann S, Aguzzi A and Birchmeier C: Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature. 376:768–771. 1995. View Article : Google Scholar : PubMed/NCBI
23	Grant DS, Kleinman HK, Goldberg ID, et al: Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA. 90:1937–1941. 1993. View Article : Google Scholar : PubMed/NCBI
24	Trusolino L and Comoglio PM: Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer. 2:289–300. 2002. View Article : Google Scholar : PubMed/NCBI
25	Michalopoulos GK and DeFrances MC: Liver regeneration. Science. 276:60–66. 1997. View Article : Google Scholar
26	Sonnenberg E, Meyer D, Weidner KM and Birchmeier C: Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol. 123:223–235. 1993. View Article : Google Scholar
27	Mizuno S and Nakamura T: Hepatocyte growth factor: a regenerative drug for acute hepatitis and liver cirrhosis. Regen Med. 2:161–170. 2007. View Article : Google Scholar : PubMed/NCBI
28	Trusolino L, Bertotti A and Comoglio PM: MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 11:834–848. 2010. View Article : Google Scholar : PubMed/NCBI
29	You WK and McDonald DM: The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep. 41:833–839. 2008. View Article : Google Scholar : PubMed/NCBI
30	Sattler M, Reddy MM, Hasina R, Gangadhar T and Salgia R: The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol. 3:171–184. 2011. View Article : Google Scholar : PubMed/NCBI
31	Gumustekin M, Kargi A, Bulut G, et al: HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer. Pathol Oncol Res. 18:209–218. 2012. View Article : Google Scholar : PubMed/NCBI
32	El-Attar HA and Sheta MI: Hepatocyte growth factor profile with breast cancer. Indian J Pathol Microbiol. 54:509–513. 2011. View Article : Google Scholar : PubMed/NCBI
33	Previdi S, Maroni P, Matteucci E, Broggini M, Bendinelli P and Desiderio MA: Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways. Eur J Cancer. 46:1679–1691. 2010. View Article : Google Scholar : PubMed/NCBI
34	Kim EJ, Eom SJ, Hong JE, Lee JY, Choi MS and Park JH: Benzyl isothiocyanate inhibits basal and hepatocyte growth factor-stimulated migration of breast cancer cells. Mol Cell Biochem. 369:431–440. 2012. View Article : Google Scholar : PubMed/NCBI
35	Derman MP, Chen JY, Spokes KC, Songyang Z and Cantley LG: An 11-amino acid sequence from c-met initiates epithelial chemotaxis via phosphatidylinositol 3-kinase and phospholipase C. J Biol Chem. 271:4251–4255. 1996. View Article : Google Scholar : PubMed/NCBI
36	Li C, Wu JJ, Hynes M, et al: c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology. 141:2218–2227. 2011. View Article : Google Scholar : PubMed/NCBI
37	Lee YJ, Kim DH, Lee SH, Kim DW, Nam HS and Cho MK: Expression of the c-Met proteins in malignant skin cancers. Ann Dermatol. 23:33–38. 2011. View Article : Google Scholar : PubMed/NCBI
38	Syed ZA, Yin W, Hughes K, Gill JN, Shi R and Clifford JL: HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop. BMC Cancer. 11:1802011. View Article : Google Scholar : PubMed/NCBI
39	Yoshizawa Y, Yamada Y, Kanayama S, et al: Signaling pathway involved in cyclooxygenase-2 up-regulation by hepatocyte growth factor in endometrial cancer cells. Oncol Rep. 26:957–964. 2011.PubMed/NCBI
40	You H, Ding W, Dang H, Jiang Y and Rountree CB: c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology. 54:879–889. 2011. View Article : Google Scholar : PubMed/NCBI
41	Osada S, Kanematsu M, Imai H and Goshima S: Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology. 55:544–549. 2008.PubMed/NCBI
42	Eksioglu-Demiralp E, Akdeniz T and Bayik M: Aberrant expression of c-met and HGF/c-met pathway provides survival advantage in B-chronic lymphocytic leukemia. Cytometry B Clin Cytom. 80:1–7. 2011. View Article : Google Scholar : PubMed/NCBI
43	Que W and Chen J: Knockdown of c-Met inhibits cell proliferation and invasion and increases chemosensitivity to doxorubicin in human multiple myeloma U266 cells in vitro. Mol Med Rep. 4:343–349. 2011.PubMed/NCBI
44	Inno A, Salvatore MD, Cenci T, et al: Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer. 10:325–332. 2011. View Article : Google Scholar : PubMed/NCBI
45	Bu R, Uddin S, Bavi P, et al: HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma. Lab Invest. 91:124–137. 2011. View Article : Google Scholar : PubMed/NCBI
46	Zhou XY, Tomatsu S, Fleming RE, et al: HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc Natl Acad Sci USA. 95:2492–2497. 1998. View Article : Google Scholar : PubMed/NCBI
47	Xue X, Taylor M, Anderson E, et al: Hypoxia-inducible factor-2alpha activation promotes colorectal cancer progression by dysregulating iron homeostasis. Cancer Res. 72:2285–2293. 2012. View Article : Google Scholar : PubMed/NCBI
48	Ba Q, Hao M, Huang H, et al: Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies. Clin Cancer Res. 17:7625–7633. 2011. View Article : Google Scholar : PubMed/NCBI
49	Zhang C and Saunders AJ: An emerging role for Ubiquilin 1 in regulating protein quality control system and in disease pathogenesis. Discov Med. 8:18–22. 2009.PubMed/NCBI
50	Guidi F, Puglia M, Gabbiani C, et al: 2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds. Mol Biosyst. 8:985–993. 2012. View Article : Google Scholar : PubMed/NCBI
51	Menashe I, Figueroa JD, Garcia-Closas M, et al: Large-scale pathway-based analysis of bladder cancer genome-wide association data from five studies of European background. PLoS One. 7:e293962012. View Article : Google Scholar : PubMed/NCBI
52	Zhang Y and Zhang B: TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res. 6:1861–1871. 2008. View Article : Google Scholar : PubMed/NCBI
53	Bolden SW, Hambley JW, Johnston GA and Rogers LJ: Neonatal stress and long-term modulation of GABA receptors in rat brain. Neurosci Lett. 111:258–262. 1990. View Article : Google Scholar : PubMed/NCBI
54	Burgett AW, Poulsen TB, Wangkanont K, et al: Natural products reveal cancer cell dependence on oxysterol-binding proteins. Nat Chem Biol. 7:639–647. 2011. View Article : Google Scholar : PubMed/NCBI